	US 12,285,475 B2
	Bacterium capable of inducing TH1 cells
Kenya Honda, Tokyo (JP); Koji Atarashi, Tokyo (JP); Seiko Narushima, Tokyo (JP); Wataru Suda, Tokyo (JP); and Masahira Hattori, Tokyo (JP)
Assigned to KEIO UNIVERSITY, Tokyo (JP)
Appl. No. 16/346,782
Filed by KEIO UNIVERSITY, Tokyo (JP)
PCT Filed Nov. 1, 2017, PCT No. PCT/JP2017/039522 § 371(c)(1), (2) Date Jul. 29, 2019, PCT Pub. No. WO2018/084172, PCT Pub. Date May 11, 2018.
Claims priority of provisional application 62/533,844, filed on Jul. 18, 2017.
Claims priority of provisional application 62/415,759, filed on Nov. 1, 2016.
Prior Publication US 2023/0293656 A1, Sep. 21, 2023
Int. Cl. A61K 39/02 (2006.01); A61K 39/108 (2006.01); A61K 39/39 (2006.01); A61P 37/04 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0266 (2013.01) [A61K 39/39 (2013.01); A61P 37/04 (2018.01); G01N 33/5044 (2013.01); A61K 2039/52 (2013.01); A61K 2039/57 (2013.01)]

4 Claims

1. A method for suppressing Th1 cell proliferation or activation in a subject, the method comprising administering the subject with an antibiotic having an antibacterial activity against a bacterium that induces Th1 cell proliferation or activation in an intestine,

wherein the bacterium is Klebsiella pneumoniae 2H7 (Kp-2H7) or Klebsiella aeromobilis 11E12 (Ka-11E12);

the antibiotic against Kp-2H7 is one or more selected from the group consisting of meropenem, tetracycline, polymyxin-B, trimethoprim, and gentamycin; and

the antibiotic against Ka-11E12 is one or more selected from the group consisting of meropenem, tetracycline, trimethoprim, ampicillin, gentamycin, streptomycin, and spectinomycin.